Drug Trial Radar · NCT07155174
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Nov 25, 2025
Primary completion
Apr 2029
Study completion Sep 2031
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide. In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Conditions
- Small Cell Lung Cancer
Interventions
ABBV-706Drug
Intravenous (IV) Infusion
AtezolizumabDrug
IV Infusion
EtoposideDrug
IV Infusion
CarboplatinDrug
IV Injection
CarboplatinDrug
IV Infusion
LurbinectedinDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)sTime frame: Up to 69.5 Months
- Progression-Free Survival (PFS) Based on Investigator AssessmentTime frame: Up to Approximately 24 Months
Locations
70 sites in 13 countries. Site status is shown where the registry gives one.
Yale University School of Medicine /ID# 278181
New Haven, Connecticut · Recruiting
University of Florida College of Medicine /ID# 277496
Gainesville, Florida · Recruiting
Ocala Oncology Center /ID# 278269
Ocala, Florida · Recruiting
Moffitt Cancer Center /ID# 277573
Tampa, Florida · Recruiting
Fort Wayne Medical Oncology And Hematology /ID# 277336
Fort Wayne, Indiana · Recruiting
Baptist Health Lexington /ID# 277729
Lexington, Kentucky · Recruiting
Dana-Farber Cancer Institute /ID# 277732
Boston, Massachusetts · Recruiting
Henry Ford Hospital - Detroit /ID# 277218
Detroit, Michigan · Recruiting
Missouri Cancer Associates /ID# 278299
Columbia, Missouri · Recruiting
University Hospitals Cleveland Medical Center /ID# 277556
Cleveland, Ohio · Recruiting
The University of Texas MD Anderson Cancer Center /ID# 277929
Houston, Texas · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 278298
Fairfax, Virginia · Recruiting
Groupe Sante CHC - Clinique du MontLegia /ID# 276783
Liège, Belgium · Recruiting
Grand Hopital de Charleroi - Les Viviers /ID# 276897
Charleroi, Hainaut, Belgium · Recruiting
Jessa Ziekenhuis - Campus Virga Jesse /ID# 276781
Hasselt, Limburg, Belgium · Recruiting
AZ Maria Middelares /ID# 277027
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Cancer Hospital - Chinese Academy of Medical Sciences /ID# 277167
Beijing, Beijing Municipality, China · Recruiting
Henan Cancer Hospital /ID# 277059
Zhengzhou, Henan, China · Recruiting
Union Hospital Tongji Medical College /ID# 277912
Wuhan, Hubei, China · Recruiting
The First affiliated hospital of Nanchang University /ID# 277247
Nanchang, Jiangxi, China · Recruiting
Shanghai East Hospital /ID# 277111
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital /ID# 276960
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University /ID# 277852
Chengdu, Sichuan, China · Recruiting
Evangelische Lungenklinik Berlin /ID# 277094
Berlin, Germany · Recruiting
Lungenfachklinik Immenhausen /ID# 278005
Immenhausen, Hesse, Germany · Recruiting
Universitaetsklinikum Giessen und Marburg GmbH /ID# 277466
Marburg, Hesse, Germany · Recruiting
Rambam Health Care Campus- Haifa /ID# 276663
Haifa, Israel · Recruiting
Hadassah Medical Center-Hebrew University /ID# 276662
Jerusalem, Israel · Recruiting
Meir Medical Center /ID# 277292
Kefar Sava, Central District, Israel · Recruiting
Assuta Ashdod Medical Center /ID# 276661
Ashdod, Southern District, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 276660
Ramat Gan, Tel Aviv, Israel · Recruiting
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 277744
Roma, Italy · Recruiting
IRCCS Ospedale San Raffaele /ID# 276793
Milan, Milano, Italy · Recruiting
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 276792
Rome, Roma, Italy · Recruiting
Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 276789
Orbassano, Torino, Italy · Recruiting
National Cancer Center Hospital East /ID# 277239
Kashiwa-shi, Chiba, Japan · Recruiting
Shizuoka Cancer Center /ID# 277243
Sunto-gun, Shizuoka, Japan · Recruiting
Tokyo Metropolitan Komagome Hospital /ID# 277335
Bunkyo Ku, Tokyo, Japan · Recruiting
National Cancer Center Hospital /ID# 277237
Chuo-Ku, Tokyo, Japan · Recruiting
Wakayama Medical University Hospital /ID# 277260
Wakayama, Wakayama, Japan · Recruiting
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.